Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial - Robert, C; Ribas, A; Wolchok, J D (Lancet, 2014)
(9948)